Swefot trial

Here we report the 2 year follow-up assessment. Methods: In this randomised, non-blinded, parallel-group trial, we enrolled adult patients older than 18 years with rheumatoid arthritis and a symptom duration of less than 1 year from 15 rheumatology units in Sweden between December, and December, All patients were started on methotrexate.

After months, those who failed treatment were randomly assigned to group A conventional treatment; additional sulfasalazine and hydroxychloroquine or group B biological treatment; additional infliximab. Results: During the 2-year follow-up, the proportion of patients testing positive declined significantly regarding antibodies to cVim, cFib and CEP-1, while anti-CCP antibody occurrence remained stable over time.

Turning anti-cVim antibody negative was most common, and anti-cVim antibody seroreversion during the first three months associated with significantly less 2-year radiographic progression compared with patients who remained positive. Cochrane Database Syst Rev. PubMed Google Scholar. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission.

A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis Swefot trial : 1-year results of a randomised trial.

Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Therapies for active rheumatoid arthritis after methotrexate failure.

N Engl J Med. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. Similar clinical outcomes in rheumatoid arthritis with more versus less expensive treatment strategies.

Observational data from two rheumatology clinics. Clin Exp Rheumatol. Epigenetic methylation and expression of caspase 8 and survivin in hepatocellular carcinoma. Pathol Int. Br J Cancer. Survivin and pAkt as potential prognostic markers in squamous cell carcinoma of the head and neck.

Clinicopathological significance of PI3K, Akt and survivin expression in gastric cancer. Biomed Pharmacother. Altieri DC. Survivin and IAP proteins in cell-death mechanisms. Biochem J. Survivin beyond physiology: orchestration of multistep carcinogenesis and therapeutic potentials. Cancer Lett. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med. Developmentally regulated expression of the novel cancer anti-apoptosis gene survivin in human and mouse differentiation.

Am J Pathol. Fukuda S, Pelus LM. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. Survivin but not Fms-like tyrosine kinase 3 ligand is up-regulated before the onset of rheumatoid arthritis: a pilot study. Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study.

Recognizing rheumatoid arthritis: oncoprotein survivin opens new possibilities: a population-based case—control study. Medicine Baltimore. Activation of Fms-like tyrosine kinase 3 signaling enhances survivin expression in a mouse model of rheumatoid arthritis.

Plos One. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J Exp Med. Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation.

Suppressed diversity of survivin splicing in active rheumatoid arthritis. Balance between survivin, a key member of the apoptosis inhibitor family, and its specific antibodies determines erosivity in rheumatoid arthritis. Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis.

Ann Med. High survivin levels predict poor clinical response to infliximab treatment in patients with rheumatoid arthritis. Semin Arthritis Rheum. Increased extracellular survivin in the synovial fluid of rheumatoid arthritis patients: fibroblast-like synoviocytes as a potential source of extracellular survivin. Available at: www. In early rheumatoid arthritis, patients with a good initial response to methotrexate have excellent 2-year clinical outcomes, but radiological progression is not fully prevented: data from the methotrexate responders population in the SWEFOT trial.

Association of cigarette smoking with the expression of nuclear survivin in pathological Stage IA lung adenocarcinomas. Med Mol Morphol. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. Arthritis Rheum. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis the BeSt study : a randomized, controlled trial. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts.

Implementation of a treat-to-target strategy in very early rheumatoid arthritis: results of the Dutch Rheumatoid Arthritis Monitoring remission induction cohort study. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res Hoboken. Article Google Scholar. Genome-wide association analysis of anti-TNF drug response in patients with rheumatoid arthritis.

Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Both of these issues will potentially be addressed in the TEAR Treatment of Early Rheumatoid Arthritis trial, the results of which have not yet been reported.

Founded in , the Arthritis Center at Johns Hopkins is dedicated to providing quality education to patients and healthcare providers alike.

All information contained within the Johns Hopkins Arthritis Center website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.